Pharmaceutical - Cardio-vascular

Filter

Current filters:

Cardio-vascular

Popular Filters

1 to 25 of 417 results

Actelion submits New Drug Application to the FDA for pulmonary arterial hypertension drug Uptravi

Actelion submits New Drug Application to the FDA for pulmonary arterial hypertension drug Uptravi

23-12-2014

Swiss biotech company Actelion has submitted a New Drug Application to the US Food and Drug Administration…

ActelionCardio-vascularPharmaceuticalRegulationselexipagSwitzerland

Cardiome links with Eddingpharm for Brinavess in China

22-12-2014

Canadian drugmaker Cardiome Pharma has entered into an agreement with Chinese firm Eddingpharm to develop…

BrinavessCardio-vascularCardiome PharmaChinaEddingpharmLicensingPharmaceuticalTaiwan

The Medicines Company and SciClone partner for cardiovasculars in China

The Medicines Company and SciClone partner for cardiovasculars in China

19-12-2014

US drugmaker The Medicines Company and SciClone Pharmaceuticals, a USA-based, China focused specialty…

AngiomaxCardio-vascularChinaCleviprexLicensingPharmaceuticalSciClone PharmaceuticalsThe Medicines Company

FDA sends Pozen a second Complete Response Letter regarding Yosprala manufacturing issues

FDA sends Pozen a second Complete Response Letter regarding Yosprala manufacturing issues

18-12-2014

US pharma company Pozen has received a second complete response letter from the US Food and Drug Administration…

Cardio-vascularPharmaceuticalPozenRegulationUSAYosprala 325/40Yosprala 81/40

Lundbeck to stop further development of desmoteplase

Lundbeck to stop further development of desmoteplase

18-12-2014

Following evaluation of disappointing clinical results, Danish CNS specialists Lundbeck said late yesterday…

Cardio-vasculardesmoteplaseFinancialLundbeckNeurologicalPharmaceuticalResearch

Portola’s andexanet alfa reverses Eliquis anticoagulant effect

Portola’s andexanet alfa reverses Eliquis anticoagulant effect

17-12-2014

A Phase III clinical trial has found that Portola Pharmaceuticals' andexanet alfa reverses the effects…

andexanet alfaBristol-Myers SquibbCardio-vascularEliquisPfizerPharmaceuticalPortola PharmaceuticalsResearchUSA

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

NICE backs Pradaxa for treating and preventing potentially fatal blood clots

17-12-2014

In final guidance published today, UK health cost watchdog the National Institute for Health and Care…

Boehringer IngelheimCardio-vascularPharmaceuticalPradaxaPricingRegulationUK

Roche's Gazyvaro and Bayer’s Adempas approved by Scottish Medicines Consortium

Roche's Gazyvaro and Bayer’s Adempas approved by Scottish Medicines Consortium

08-12-2014

The Scottish Medicines Consortium has decided to grant access to Gazyvaro (obinutuzumab), manufactured…

AdempasBayerCardio-vascularGazyvaroOncologyPharmaceuticalRegulationRoche

Mixed findings from IQWiG on added benefit for Eliquis

05-12-2014

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined a dossier on Eliquis…

Bristol-Myers SquibbCardio-vascularEliquisGermanyPfizerPharmaceuticalPricingRegulation

Actelion submits selexipag for EMA marketing authorization in PAH

Actelion submits selexipag for EMA marketing authorization in PAH

03-12-2014

Swiss biotech firm Actelion has submitted a centralized Marketing Authorization Application to the European…

ActelionCardio-vascularEuropePharmaceuticalRegulationselexipag

Novartis’ heart failure drug LCZ696 granted accelerated assessment by CHMP

Novartis’ heart failure drug LCZ696 granted accelerated assessment by CHMP

28-11-2014

Swiss drug major Novartis announced that the European Medicines Agency’s Committee for Medicinal Products…

Cardio-vascularEuropeLCZ696NovartisPharmaceuticalRegulation

EMA makes recommendation for reducing heart attack risk of Servier's Corlentor/Procoralan

EMA makes recommendation for reducing heart attack risk of Servier's Corlentor/Procoralan

21-11-2014

The European Medicines Agency has reviewed angina medication Corlentor/Procoralan (ivibradine), manufactured…

Cardio-vascularEuropePharmaceuticalProcoralanRegulationServier

Sanofi showcases next wave of medicines and vaccines

20-11-2014

French pharma major Sanofi is today outlining its intention to launch high-potential new medicines and…

Cardio-vascularDiabetesHealth Medical PharmaImmunologicalsNeurologicalPharmaceuticalPharmaceutical industryRare diseasesResearchSanofiUnited StatesVaccines

Positive early results for Boehringer Ingelheim’s investigational antidote idarucizumab

19-11-2014

The US subsidiary of German family-owned pharma major Boehringer Ingelheim has presented Phase I study…

Boehringer IngelheimCardio-vascularHematologyidarucizumabPharmaceuticalPradaxaResearch

Novartis’ LCZ696 reduces the risk of dying and hospitalizations

Novartis’ LCZ696 reduces the risk of dying and hospitalizations

18-11-2014

New data on Swiss drug major Novartis’ investigational medicine LCZ696, for patients with heart failure…

Cardio-vascularLCZ696NovartisPharmaceuticalResearchSwitzerland

AstraZeneca reinforces target of $45 billion revenues by 2023

AstraZeneca reinforces target of $45 billion revenues by 2023

18-11-2014

Anglo-Swedish pharma major AstraZeneca today provided an update for institutional investors and financial…

AstraZenecaCardio-vascularFinancialInflammatory diseasesMetabolicsOncologyPharmaceuticalRespiratory and PulmonaryUK

Merck & Co’s LDL-lowering drug Vytorin meets study endpoints

Merck & Co’s LDL-lowering drug Vytorin meets study endpoints

18-11-2014

Pharma giant Merck & Co has announced that the study investigating LDL-cholesterol-lowering drug Vytorin…

Cardio-vascularMerck & CoPharmaceuticalResearchUSAVytorinZetia

Extended benefit of dual antiplatelet therapy after one year is proven in study

Extended benefit of dual antiplatelet therapy after one year is proven in study

18-11-2014

New research published in the New England Journal of Medicine shows that while dual antiplatelet therapy…

Cardio-vascularClopidogrelPharmaceuticalprasugrelResearchUSA

Study shows mutations in NPC1L1 protein cut coronary heart disease

Study shows mutations in NPC1L1 protein cut coronary heart disease

14-11-2014

A new study part-funded by US pharma giant Merck & Co (NYSE: MRK) has found that mutations in a gene…

Cardio-vascularCoronary heart diseaseMerck & CoPharmaceuticalResearchUnited StatesUSAZetia

Biologics will complement statins in cholesterol treatment space, says GlobalData

Biologics will complement statins in cholesterol treatment space, says GlobalData

11-11-2014

Biologics will play an influential role in shaping the future of cardiovascular drug treatment, in particular…

alirocumabAmgenCardio-vascularevolocumabMarkets & MarketingPharmaceuticalRegeneronSanofiUSA

ScinoPharm and Nanjing King-friend team up to market new drugs in China

ScinoPharm and Nanjing King-friend team up to market new drugs in China

10-11-2014

ScinoPharm Taiwan and China’s Nanjing King-friend Biochemical Pharmaceutical (NKF) announced today…

Cardio-vascularChinaMarkets & MarketingNanjing King-friend BiochemicalPharmaceuticalRegadenoson InjectionResearchScinoPharma Taiwan

EMA PRAC’s recommendations to reduce risk of heart problems with ivabradine

09-11-2014

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a…

AmgenCardio-vascularEuropeivabradinePharmaceuticalProcoralanRegulationServier

Pharming and Salix's Ruconest launches in the USA for hereditary angioedema

Pharming and Salix's Ruconest launches in the USA for hereditary angioedema

03-11-2014

Pharming Group and Salix Pharmaceuticals have launched Ruconest (C1 esterase inhibitor) in the USA for…

Cardio-vascularMarkets & MarketingPharmaceuticalPharming Group NVRuconestSalixUSA

1 to 25 of 417 results

Back to top